22 June 2020: Clinical Research
Association of Serum Thyroid Hormones with the Risk and Severity of Chronic Kidney Disease Among 3563 Chinese Adults
Jialin Li 1CE , Xi’ai Wu 2BD , Minjing Luo 1BF , Meihua Yan 3BD , Qian Wang 1D , Ping Li 3AG* , Wenquan Niu 3CE*DOI: 10.12659/MSM.922910
Med Sci Monit 2020; 26:e922910
Table 1 Baseline characteristics of study participants in this retrospective study.
| Characteristics | Controls | Patients with chronic kidney disease (CKD) | |||
|---|---|---|---|---|---|
| Stage 1–2 | Stage 3 | Stage 4 | Stage 5 | ||
| Sample size | 289 | 471 | 544 | 1214 | 1045 |
| Age (years) | 62 (53–69) | 68 (56–75)** | 73 (65–77)** | 70 (60–76)** | 59 (47–68)** |
| Male (n, %) | 236, 81.7 | 325, 69** | 428, 78.7 | 819, 67.5** | 588, 56.3** |
| Hypertension (n, %) | 175, 60.6 | 308, 65.4 | 354, 65.1 | 875, 72.1** | 819, 78.36** |
| Diabetes (n, %) | 111, 38.4 | 179, 38.0 | 211, 38.8 | 544, 44.8* | 356, 34.1 |
| TG (mmol/L) | 1.38 (1.00–1.90) | 1.32 (0.94–2.03) | 1.36 (0.95–1.95) | 1.51 (1.05–2.20)** | 1.54 (1.08–2.19)** |
| TC (mmol/L) | 4.30 (3.52–4.96) | 4.02 (3.08–4.80)** | 3.720 (2.94–4.57)** | 3.950 (3.16–4.94)** | 4.18 (3.45–5.00) |
| LDL-C (mmol/L) | 2.56 (1.98–3.08) | 2.29 (1.59–2.92)** | 2.11 (1.49–2.74)** | 2.29 (1.64–3.06)** | 2.42 (1.88–3.09) |
| HDL-C (mmol/L) | 1.01 (0.84–1.21) | 0.97 (0.72–1.22)* | 0.86 (0.61–1.08)** | 0.91 (0.68–1.17)** | 1.00 (0.78–1.24) |
| HbA1c (%) | 6.10 (5.50–7.10) | 6.20 (5.50–7.20) | 6.40 (5.80–7.30)* | 6.40 (5.70–7.30)* | 5.90 (5.30–6.70)** |
| UA (μmol/L) | 333 (285–387) | 314 (218–444) | 384 (274–500)** | 442 (345–548)** | 404 (316–502)** |
| Scr (μmol/L) | 75 (66.10–85) | 77.40 (62.90–92.65) | 143.8 (121–169)** | 236 (203.3–283)** | 635.9 (463.6–859)** |
| ACR (mg/g) | 5.70 (4.20–9.10) | 64.80 (44.10–80.30)** | 21.35 (6.60–62.10)** | 126.9 (36.10–317.30)** | 220.6 (126.30–429.50)** |
| BUN (mmol/L) | 5.44 (4.46–6.75) | 9.07 (5.72–14.88)** | 11.65 (8.86–15.89)** | 15.24 (11.79–20.13)** | 21.24 (16.10–27.36)** |
| T3 (ng/mL) | 0.97 (0.86–1.08) | 0.76 (0.61–0.95)** | 0.63 (0.47–0.81)** | 0.70 (0.52–0.87)** | 0.74 (0.57–0.93)** |
| T4 (μg/dL) | 7.22 (6.21–8.30) | 6.76 (5.58–8.40)* | 6.20 (4.80–7.70)** | 6.51 (5.33–7.82)** | 6.30 (5.17–7.61)** |
| FT3 (pg/mL) | 2.88 (2.64–3.09) | 2.23 (1.79–2.69)** | 2.00 (1.50–2.43)** | 2.07 (1.60–2.47)** | 2.15 (1.69–2.58)** |
| FT4 (ng/dL) | 1.19 (1.08–1.34) | 1.15 (1.00–1.32)** | 1.15 (0.96–1.37)* | 1.15 (0.98–1.31)** | 1.10 (0.93–1.27)** |
| TSH (μIU/mL) | 1.79 (1.20–2.71) | 1.46 (0.72–2.37)* | 1.53 (0.65–3.23) | 2.17 (1.14–4.10)* | 2.23 (1.28–3.75)** |
| P values are calculated by nonparametric Wilcoxon rank sum tests for continuous variables expressed as median (interquartile range) and χ tests for categorical variables expressed as count and percent. TG – triglycerides; TC – total cholesterol; LDL-C – low-density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; UA – uric acid; Scr – serum creatinine; ACR – albumin-to-creatinine ratio; BUN – blood urea nitrogen; T3 – total triiodothyronine; T4 – total thyroxine; FT3 – free triiodothyronine; FT4 – free thyroxine; TSH – thyroid-stimulating hormone. * P ** P | |||||